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Background: Several accurate glycemic control (AGC) protocols for critical care patients exist but 
making comparisons is very hard. 
Objective: This study uses clinically validated virtual patient methods to compare safety and 
performance for several published AGC protocols.  
Method: Clinically validated virtual trials were run on 371 patients (39,481 hours, 26,646 
measurements) created from the SPRINT AGC cohort. For protocols that do not modulate feed rates 
enteral nutrition was held at 100% of ACCP goal (25kcal/kg/day) when the patients were clinically 
fed, and parenteral nutrition rates were matched to clinical data. Performance was defined as %BG 
within glycemic bands and BG measurement frequency. Safety was defined as the incidence of severe 
(number patients with BG<40mg/dL) and moderate (%BG<72mg/dL) hypoglycemia. Clinical data 
from SPRINT is also compared. 
Results: Clinical SPRINT performance data matched re-simulated SPRINT with 86% vs. 86% BG in 
80-145mg/dL, 2.00% vs. 2.07% BG above 180mg/dL and 7.83% vs. 7.29% BG below 72mg/dL, with 
14 measurements (over 8 patients) of BG<40mg/dL. Yale results were 83.5%, 3.20%, 5.18%, with 6 
severe hypoglycemic patients, using 37,961 measurements (23.0/day). Glucontrol had 75.2%, 3.70%, 
9.45%, 52 cases and 26,199 measurements (15.8/day). Braithwaite had 84.2%, 3.00%, 4.22%, 19 
cases and 24,396 measurements (14.8/day). The STAR (Stochastic TARgeted) model-based method 
had 90.6%, 1.67%, 1.33%, 5 cases and 20,591 measurements (12.3/day). 
Conclusions: Virtual trials provided an effective comparison across protocols with different target 
bands/values and different clinical cohorts. The model-based STAR protocol provided the best 
management of patient variability yielding the best performance and safety. 
 
